The German CML-Study IV randomized 1,014 patients to one of the three cohorts: 1) monotherapy imatinib 400 mg QD; 2) imatinib 400 mg QD plus IFNα (1.5–3 mill. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.